Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
7 hedge funds and large institutions have $377K invested in Genetic Technologies Ltd. in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
99% more capital invested
Capital invested by funds: $189K → $377K (+$188K)
17% more funds holding
Funds holding: 6 → 7 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$315K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$96.1K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$7.87K |
| 4 |
Morgan Stanley
New York
|
+$1.13K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$574 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$633 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $210K | +$315K | +140,000 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $115K | +$96.1K | +42,707 | +123% |
|
|
3
Morgan Stanley
New York
| $27K | +$1.13K | +500 | +3% |
|
|
4
BNP Paribas Financial Markets
Paris,
France
| $18.9K | +$7.87K | +3,500 | +38% |
|
5
RhumbLine Advisers
Boston,
Massachusetts
| $5.57K | – | – | – |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $600 | – | – | – |
|
|
7
UBS Group
Zurich,
Switzerland
| – | -$633 | -219 | Closed |
|
|
8
Simplex Trading
Chicago,
Illinois
| – | +$574 | +255 | New |
|
GENE Hedge Fund Activity: Q2 2024 in Review
7 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q2 2024, worth a combined $377K — up 99% from $189K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new GENE positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $315K. The largest seller was UBS Group, exiting entirely with an estimated $633 sold.
- 7 institutional investors held Genetic Technologies Ltd. (GENE) as of Q2 2024, up from 6 in Q1 2024.
- Funds reported $377K of Genetic Technologies Ltd. stock for Q2 2024, up 99% quarter-over-quarter.
- 2 funds opened new Genetic Technologies Ltd. positions in Q2 2024 and 1 closed out, a net change of +1 holder.
- The largest Genetic Technologies Ltd. buyer in Q2 2024 was Armistice Capital, an estimated $315K added.
- The largest Genetic Technologies Ltd. seller in Q2 2024 was UBS Group, an estimated $633 sold.
Based on aggregated 13F filings for Q2 2024.